Table 2 Treatment modification based on patients’ tolerance during the study in the safety analysis set
Treatment modification | Famitinib group [cases (%)] | Placebo group [cases (%)] |
|---|---|---|
Treatment interruption | 49 (49.5) | 13 (23.6) |
 Once | 26 (26.3) | 12 (21.8) |
 Twice | 8 (8.1) | 1 (1.8) |
 More than twice | 15 (15.2) | 0 |
Dose reduction | 24 (24.2) | 2 (3.6) |
 One reduction | 19 (19.2) | 1 (1.8) |
 Two reductions | 5 (5.1) | 1 (1.8) |